Condition
Stage I Non-Small Cell Lung Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
5 shownOsimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before SurgeryNCT03433469 · 2018-07-31
ACTIVE_NOT_RECRUITINGAtezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung CancerNCT02599454 · 2018-04-26
COMPLETEDNivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung CancerNCT03366766 · 2017-12-20
TERMINATEDTG4010 and Nivolumab in Patients With Lung CancerNCT02823990 · 2016-12-14
COMPLETEDFeasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung CarcinomaNCT02319889 · 2016-02-02
TERMINATEDCommon interventions
NivolumabBIOLOGICAL2AtezolizumabDRUG1CarboplatinDRUG1CisplatinDRUG1Gemcitabine HydrochlorideDRUG1OsimertinibDRUG1Paclitaxel Albumin-Stabilized Nanoparticle FormulationDRUG1Pemetrexed DisodiumDRUG1Stereotactic Body Radiation TherapyRADIATION1Stereotactic Body RadiotherapyRADIATION1TG4010BIOLOGICAL1Therapeutic Conventional SurgeryPROCEDURE1
Leading sponsors
Trial status mix
COMPLETED2
TERMINATED2
ACTIVE_NOT_RECRUITING1
Phase mix
PHASE23
EARLY_PHASE11
PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.